Great progress has been made in the development of clinical CAR-T cell therapies. The autologous CAR-T cell approaches in the clinic today are extremely effective but have been associated with significant toxicities and are very expensive. The use of allogeneic, off-the-shelf CAR therapies using natural killer cells from several different sources will be reviewed as potentially less toxic and less expensive immune effector cell products to treat cancer patients.

Citation Format: Elizabeth J. Shpall. The future of CAR therapies [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr IA13.